Drug therapy for the prevention and treatment of bronchopulmonary dysplasia.

摘要: Introduction: As more infants are surviving at younger gestational ages, bronchopulmonary dysplasia (BPD) remains as a frequent neonatal complication occurring after preterm birth. The multifactorial nature of the disease process makes BPD challenging condition to treat. While multiple pharmacologic therapies have been investigated over past two decades, there limited advances in field. Often used concurrently without clear evidence efficacy, with potential for significant side effects from drug-drug interactions. Methods: Systematic literature review. Conclusion: Although is physiologic rationale use many these therapies, none them has single-handedly altered incidence, severity, or progression BPD. Future research should focus on developing clinically end-points (short and long term respiratory assessments), investigating biomarkers that accurately predict risk disease, creating appropriate stratification models severity. Applying multi-modal approach study new existing drugs be most effective way establishing optimal prevention treatment regimens